Stocktoria
LB PHARMACEUTICALS INC LBRX
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2025-09-11
LB PHARMACEUTICALS INC financials (annual, from 10-K)
| Metric | FY2025 | FY2024 |
|---|---|---|
| R&D expense | $16.7M | $51.2M |
| Income tax | $1,000 | $1,000 |
| Net income | -$25.2M | -$63.1M |
| EPS (diluted) | $-3.13 | $-176.15 |
| Operating cash flow | -$35.2M | -$53.1M |
| Free cash flow | -$35.3M | -$53.8M |
| Cash & equivalents | $250.2M | $23.0M |
| Total assets | $312.9M | $33.5M |
| Total liabilities | $11.6M | $13.8M |
| Shareholders' equity | $301.3M | -$94.6M |
Source: SEC EDGAR filings · CIK 0001691082 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.